KMT2D and diffuse large B-cell lymphoma: The expression of KMT2D was correlated with Ann Arbor stage in EBV+ DLBCL and IPI score in both EBV+ and EBV-negative DLBCL (P < 0.05), indicating that KMT2D may participate in the growth and progression in DLBCL.